Table 4.
GDMT Usea |
Sample Size | Outcome: Death or HF hospitalization |
Outcome: Death |
||||
---|---|---|---|---|---|---|---|
No of Events | Rate (per 100 PY) | Adjusted HR (95% CI) |
No of Events | Rate (per 100 PY) | Adjusted HR (95% CI) |
||
Total Population | |||||||
0 classes | 5970 | 2933 | 22.8 | Reference | 2727 | 20.1 | Reference |
1 class | 30028 | 15034 | 22.3 | 0.94 (0.91, 0.97)b | 13771 | 19.3 | 0.94 (0.91, 0.97)b |
2 classes | 78302 | 34686 | 18.3 | 0.92 (0.89, 0.94)b | 30278 | 14.9 | 0.89 (0.86, 0.91)b |
3 classes | 32699 | 14976 | 18.9 | 0.94 (0.91, 0.97)b | 12649 | 14.7 | 0.88 (0.86, 0.91)b |
| |||||||
Frail | |||||||
| |||||||
0 classes | 3324 | 1927 | 29.4 | Reference | 1824 | 26.3 | Reference |
1 class | 16896 | 9867 | 28.4 | 0.95 (0.91, 0.99)c | 9269 | 25.2 | 0.95 (0.91, 0.99)c |
2 classes | 37213 | 20138 | 24.7 | 0.92 (0.89, 0.96)c | 18176 | 20.6 | 0.89 (0.85, 0.92)c |
3 classes | 15002 | 8270 | 25.3 | 0.95 (0.91, 0.99)c | 7217 | 19.9 | 0.89 (0.85, 0.92)c |
| |||||||
Non-Frail | |||||||
| |||||||
0 classes | 2646 | 1006 | 15.9 | Reference | 903 | 13.6 | Reference |
1 class | 13132 | 5167 | 15.8 | 0.93 (0.89. 0.98)c | 4502 | 13.0 | 0.92 (0.88, 0.97)c |
2 classes | 41089 | 14548 | 13.4 | 0.91 (0.87, 0.95)c | 12102 | 10.5 | 0.89 (0.85, 0.93)c |
3 classes | 17697 | 6706 | 14.5 | 0.92 (0.88, 0.96)c | 5432 | 10.9 | 0.88 (0.84, 0.92)c |
Abbreviations: CI, confidence interval; GDMT, guideline-directed medical therapy; HF, heart failure; HR, hazard ratio; PY, person-years.
GDMT use is defined as filling a prescription for the following 3 drug classes between January 1, 2015, and December 31, 2015: 1) an ARNI, ACE inhibitor, or ARB; 2) an evidence-based beta-blocker; or 3) a mineralocorticoid receptor antagonist.
The model was adjusted for age, sex, race, dual eligibility, Alzheimer’s disease and related dementias, anemia, atrial fibrillation, cancer, chronic kidney disease, chronic obstructive pulmonary disease, depression, diabetes, hip or pelvic fracture, hypertension, myocardial infarction, osteoporosis, rheumatoid arthritis or osteoarthritis, and stroke or transient ischemic attack, Gagne combined comorbidity index, frailty, cardiology visit within the past 30 days, ≥2 heart failure hospitalizations within the past year, and heart failure hospitalization within the past 30 days.
The model was adjusted for all above variables except for frailty.